RELATIONSHIP OF LYMPHOCYTE SUBPOPULATIONS IN BREAST CANCER PATIENTS WITH TREATMENT RESULTS

Cover Page

Cite item

Full Text

Abstract

Introduction. Breast cancer (BC) is an immunogenic tumor. Immune cells infiltration of tumor tissue can affect the clinical course of the disease. The immunogenicity of breast cancer varies depending on the molecular subtype.

The aim of this work was to study the main indicators of systemic and local immunity before patient’s treatment and to determine their relationship with the immediate neoadjuvant chemotherapy results.

Materials and methods. Patients with stage II–III BC received standard neoadjuvant chemotherapy in accordance with the molecular subtypes. The percentage of the main effector and regulatory lymphocytes populations of systemic and local immunity was determined by flow cytometry.

Results. A decrease in the level of effector CD8 and CD4 lymphocyte populations and an increase in the level suppressor populations in tumor tissue in comparison with peripheral blood indicate an immunosuppressive state of local immunity in BC patients. In tumor tissue, a high level of CD8+ PD-1+ and CD4+ PD-1+ cells were associated with a high level of regulatory CD4+ CD25highCD127–/low and CD8+ CD11b– CD28– lymphocytes. Differences were found in the significance of individual lymphocyte populations for the immediate results of treatment between patients with different subtypes of breast cancer.

Conclusion. Determination of lymphocyte subpopulations correlating with the level of PD-1 cells, and the results of treatment in patients with different molecular BC subtypes, will help a clearer understanding of the antitumor immune response in this pathology, and will also serve as a basis for identifying immune biomarkers that can be used as additional predictive factors in various treatment options for BC patients. 

About the authors

T. N. Zabotina

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Author for correspondence.
Email: tatzabotina@yandex.ru
ORCID iD: 0000-0001-7631-5699

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

A. I. Chertkova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0001-9146-5986

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

A. A. Borunova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0002-1854-3455

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

E. N. Zakharova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0003-2790-6673

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

E. K. Shoua

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0003-3937-474X

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

E. V. Artamonova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0001-7728-9533

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

E. I. Kovalenko

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0003-4763-7992

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

M. V. Horoshilov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0002-3770-5173

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

A. G. Kadagidze

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

ORCID iD: 0000-0002-0058-0987

24 Kashyrskoe Shosse, Moscow 115478

Russian Federation

References

  1. Harbeck N., Penault-Llorca F., Cortes J. et al. Breast cancer. Nat Rev Dis Primers 2019;5(1):66. doi: 10.1038/s41572-019-0111-2.
  2. Zhang L., Wang X.I., Ding J. et al. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Ann Diagn Pathol 2019;40:143–51. doi: 10.1016/j.anndiagpath.2019.04.004.
  3. Hammerl D., Smid M., Timmermans A.M. et al. Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol 2018;52(Pt 2):178–88. doi: 10.1016/j.semcancer.2017. 11.003.
  4. Planes-Laine G., Rochigneux P., Bertucci F. et al. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers (Basel) 2019;11(7):1033. doi: 10.3390/cancers11071033.
  5. Emens L.A. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res 2018;24(3):511– 20. doi: 10.1158/1078-0432.CCR-16-3001.
  6. Akinleye A., Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 2019;12(1):92. doi: 10.1186/s13045-019-0779-5.
  7. Han Y., Liu D., Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 2020;10(3):727–42. Available at: http://ajcr.us/files/ajcr0108072.pdf.
  8. Ai L., Xu A., Xu J. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol 2020;1248:33–59. doi: 10.1007/978-981-15-3266-5_3.
  9. Paijens S.T., Vledder A., de Bruyn M., Nijman H.W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol 2021;18(4):842–59. doi: 10.1038/s41423-020-00565-9.
  10. Lotfinejad P., Kazemi T., Mokhtarzadeh A. et al. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sci 2020;259:118297. doi: 10.1016/j.lfs.2020.118297.
  11. Schnell A., Schmidl C., Herr W., Siska P.J. The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction. Biomedicines 2018;6(1):25. doi: 10.3390/biomedicines6010025.
  12. Lavnikova G.A. Histological method for quantifying therapeutic tumor damage. Moscow: Metodicheskiye rekomendatsii, 1979. 13 p. (In Russ.).
  13. Zabotina T.N., Korotkova O.V., Borunova A.A. et al. Multiparameter study of the immunophenotype of lymphocytes infiltrating a tumor in cancer patients. Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2016;21(1–2):51–4. (In Russ.).
  14. Zabotina T.N., Chertkova A.I., Tsiklauri V.T. et al. Features of peripheral blood lymphocytes and tumor infiltrating lymphocytes subpopulations in patients with squamous cell head and neck cancer. Immunologiya = Immunology 2019;40(3):10–9. (In Russ.). doi: 10.24411/0206-4952-2019-13002.
  15. Cai J., Wang D., Zhang G., Guo X. The Role of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. Onco Targets Ther 2019;12:8437–45. doi: 10.2147/OTT.S221340.
  16. Kadagidze Z.G., Chertkova A.I., Zabotina T.N. et al. The relationship of markers of early and late lymphocytes activation with the effectiveness of neoadjuvant chemotherapy in patients with triple negative breast cancer with the efficiency of neoadjuvant chemotherapy in triple negative breast cancer patients. Immunologiya = Immunology 2021;42(2):112–24. (In Russ.). doi: 10.33029/0206-4952-2021-42-2-112-124.
  17. Zabotina T.N., Chertkova A.I., Kadagidze Z.G. et al. Peripheral blood CD8+-lymphocytes populations and its value for direct and outlying treatment results in triple negative breast cancer patients. Immunologiya = Immunology 2020;41(4):326–36. (In Russ.). doi: 10.33029/0206-4952-2020-41-3-326-336.
  18. Wu S.Y., Fu T., Jiang Y.Z., Shao Z.M. Natural killer cells in cancer biology and therapy. Mol Cancer 2020;19(1):120. doi: 10.1186/s12943-020-01238-x.
  19. Vihervuori H., Autere T.A., Repo H. et al. Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer. J Cancer Res Clin Oncol 2019;145(12):3105–14. doi: 10.1007/s00432-019-03036-5.
  20. Ali H.R., Provenzano E., Dawson S.J. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 2014;25(8):1536–43. doi: 10.1093/annonc/mdu191.
  21. deLeeuw R.J., Kost S.E., Kakal J.A., Nelson B.H. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18(11):3022–9. doi: 10.1158/1078-0432.CCR-11-3216.
  22. Shang B., Liu Y., Jiang S.J., Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015;5:15179. doi: 10.1038/srep15179.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.